exg102
Gene therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 24, 2023 (NCT05903794)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Angiopoietin-2INHIBITOR
ANGPT2 inhibitor
- Vascular endothelial growth factor CINHIBITOR
VEGFC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06183814 | Phase 1/Phase 2 (Phase 2) | Oct 12, 2023 | Government of China, Peking University |
| NCT05903794 | Phase 1 | Jul 24, 2023 | Exegenesis Bio, Sierra Eye Associates |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exegenesis Bio | For profit | 1 | 1 | 1 | 2023 |
| Government of China | Government | 1 | 1 | 1 | 2023 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Sierra Eye Associates | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1